Maintaining telomere length;Zachowanie długości telomerów

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 1319-1330

  Wysoczańska, Barbara ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

DNA repair; DNA replication; Senescence; Telomerase activity; Telomere length

Indexed keywords

SHELTERIN, HUMAN; TELOMERASE; TELOMERE BINDING PROTEIN;

ANIMAL; ARTICLE; CELL CYCLE; CHROMOSOMAL INSTABILITY; DEGENERATIVE DISEASE; DNA DAMAGE; GENETICS; HEMATOLOGIC DISEASE; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY; TELOMERE HOMEOSTASIS;

ANIMALS; CELL CYCLE; CHROMOSOMAL INSTABILITY; DNA DAMAGE; HEMATOLOGIC NEOPLASMS; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; TELOMERASE; TELOMERE HOMEOSTASIS; TELOMERE-BINDING PROTEINS;

EID: 84892620474     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1081034     Document Type: Article

References (99)

1. Alter B. P., Baerlocher G. M., Savage S. A., Chanock S. J., Weksler B. B., Willner J. P., Peters J. A., Giri N., Lansdorp P. M.: Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood, 2007;110:1439-1447
2. Alter B. P., Rosenberg P. S., Giri N., Baerlocher G. M., Lansdorp P. M., Savage S. A.: Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica, 2012;97:353-359
3. Armanios M.: Syndromes of telomere shortening. Annu. Rev. Genomics Hum. Genet., 2009;10:45-61
4. Armanios M., Blackburn E. H.: The telomere syndromes. Nat. Rev. Genet., 2012;13:693-704
5. Artandi S. E., DePinho R. A.: Telomeres and telomerase in cancer. Carcinogenesis, 2010;31;9-18
6. Aubert G., Baerlocher G. M., Vulto I., Poon S. S., Lansdorp P. M.: Collapse of telomere homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes. PLoS Genet., 2012;8:e1002696
7. Aubert G., Hills M., Lansdorp P. M.: Telomere length measurement-caveats and a critical assessment of the available technologies and tools. Mutat. Res., 2012;730:59-67
8. Aubert G., Lansdorp P. M.: Telomeres and aging. Physiol. Rev., 2008;88:557-579
9. Baird D. M.: Mechanisms of telomeric instability. Cytogenet. Genome Res., 2008;122:308-314
10. Baird D. M.: Variation at the TERT locus and predisposition for cancer. Expert Rev. Mol. Med., 2010;12:e16
11. Baumann P., Cech T. R.: Pot1, the putative telomere end-binding protein in fission yeast and humans. Science, 2001;292:1171-1175
12. Beliveau A., Bassett E., Lo A. T., Garbe J., Rubio M. A., Bissell M. J., Campisi J., Yaswen P.: p53-dependent integration of telomere and growth factor deprivation signals. Proc. Natl. Acad. Sci. USA, 2007;104:4431-4436
13. Benetos A., Okuda K., Lajemi M., Kimura M., Thomas F., Skurnick J., Labat C., Bean K., Aviv A.: Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension, 2001;37:381-385
14. Bianchi A., Shore D.: Telomeres: maintenance and replication. Encyclopedia Biol. Chem., 2004;4:174-179
15. Bilsland A. E., Cairney C. J., Keith W. N.: Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. J. Cell. Mol. Med., 2011;15:179-186
16. Blackburn E. H.: Walking the walk from genes through telomere maintenance to cancer risk. Cancer Prev. Res., 2011;4:473-475
17. Borssén M., Cullman I., Norén-Nyström U., Sundström C., Porwit A., Forestier E., Roos G.: hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup. Exp. Hematol., 2011;39:1144-1151
18. Boultwood J., Peniket A., Watkins F., Shepherd P., McGale P., Richards S., Fidler C., Littlewood T. J., Wainscoat J. S.: Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood, 2000;96:358-361
19. Broccoli D., Young J. W., de Lange T.: Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA, 1995;92:9082-9086
20. Brower V.: Telomerase-based therapies emerging slowly. J. Natl. Cancer Inst., 2010;102:520-521
21. Brümmendorf T. H., Maciejewski J. P., Mak J., Young N. S., Lansdorp P. M.: Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood, 2001;97:895-900
22. Brunsvig P. F., Aamdal S., Gjertsen M. K., Kvalheim G., Markowski-Grimsrud C. J., Sve I., Dyrhaug M., Trachsel S., Moller M., Eriksen J. A., Gaudernack G.: Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother., 2006;55:1553-1564
23. Buseman C. M., Wright W. E., Shay J. W.: Is telomerase a viable target in cancer? Mutat. Res., 2012;730:90-97
24. Calado R. T.: Telomeres and marrow failure. Hematology Am. Soc. Hematol. Educ. Program, 2009:338-343
25. Calado R. T., Regal J. A., Hills M., Yewdell W. T., Dalmazzo L. F., Zago M. A., Lansdorp P. M., Hogge D., Chanock S. J., Estey E. H., Falcao R. P., Young N. S.: Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc. Natl. Acad. Sci. USA, 2009;106:1187-1192
26. Calado R. T., Yewdell W. T., Wilkerson K. L., Regal J. A., Kajigaya S., Stratakis C. A., Young N. S.: Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood, 2009;114:2236-2243
27. Calado R. T., Young N. S.: Telomere diseases. N. Engl. J. Med., 2009;361:2353-2365
28. Campbell L. J., Fidler C., Eagleton H., Peniket A., Kusec R., Gal S., Littlewood T. J., Wainscoat J. S., Boultwood J.: hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia, 2006;20:671-679
29. Capper R., Britt-Compton B., Tankimanova M., Rowson J., Letsolo B., Man S., Haughton M., Baird D. M.: The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes Dev., 2007:21;2495-2508
30. Capraro V., Zane L., Poncet D., Perol D., Galia P., Preudhomme C., Bonnefoy-Berard N., Gilson E., Thomas X., El-Hamri M., Chelghoun Y., Michallet M., Wattel E., Mortreux F., Sibon D.: Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp. Hematol., 2011;39:195-202.e2
31. Chan S. S., Chang S.: Defending the end zone: studying the players involved in protecting chromosome ends. FEBS Lett., 2010;584:3773-3778
32. Cifuentes-Rojas C., Shippen D. E.: Telomerase regulation. Mutat. Res., 2012;730:20-27
33. Cohen S. B., Graham M. E., Lovrecz G. O., Bache N., Robinson P. J., Reddel R. R.: Protein composition of catalytically active human telomerase from immortal cells. Science, 2007;315:1850-1853
34. De Boeck G., Forsyth R. G., Praet M., Hogendoorn P. C.: Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J. Pathol., 2009;217:327-344
35. de Lange T.: How telomeres solve the end-protection problem. Science, 2009;326:948-952
36. de Lange T.: Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev., 2005;19:2100-2110
37. Denchi E. L.: Give me a break: how telomeres suppress the DNA damage response. DNA Repair, 2009;8:1118-1126
38. Denchi E. L., de Lange T.: Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature, 2007;448:1068-1071
39. Deville L., Hillion J., Ségal-Bendirdjian E.: Telomerase regulation in hematological cancers: a matter of stemness? Biochim. Biophys. Acta, 2009;1792:229-239
40. Ding Z., Wu C. J., Jaskelioff M., Ivanova E., Kost-Alimova M., Protopopov A., Chu G. C., Wang G., Lu X., Labrot E. S., Hu J., Wang W., Xiao Y., Zhang H., Zhang J. i wsp.: Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell, 2012;148:896-907
41. Diotti R., Loayza D.: Shelterin complex and associated factors at human telomeres. Nucleus, 2011;2:119-135
42. Donehover L. A.: Does p53 affect organismal aging? J. Cell. Physiol., 2002;192:23-33
43. Eisenberg D. T.: An evolutionary review of human telomere biology: the thrifty telomere hypothesis and notes on potential adaptive paternal effects. Am. J. Hum. Biol., 2011;23:149-167
44. Eisenstein M.: Telomeres: all's well that ends well. Nature, 2011;478:S13-S15
45. Fajkus J.: Detection of telomerase activity by the TRAP assay and its variants and alternatives. Clin. Chim. Acta, 2006;371:25-31
46. Gomez D. E., Armando R. G., Farina H. G., Menna P. L., Cerrudo C. S., Ghiringhelli P. D., Alonso D. F.: Telomere structure and telomerase in health and disease. Int. J. Oncol., 2012;41:1561-1569
47. González-Suárez E., Flores J. M., Blasco M. A.: Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol. Cell. Biol., 2002;22:7291-7301
48. Gonzalo S., Jaco I., Fraga M. F., Chen T., Li E., Esteller M., Blasco M. A.: DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat. Cell Biol., 2006;8:416-424
49. Gross M., Mkrtchyan H., Glaser M., Fricke H. J., Höffken K., Heller A., Weise A., Liehr T.: Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid leukemia with normal GTG-banding karyotype. Int. J. Oncol., 2009;34:417-423
50. Gu J., Chen M., Shete S., Amos C. I., Kamat A, Ye Y, Lin J., Dinney C. P., Wu X.: A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev. Res., 2011;4:514-521
51. Hartmann U., Brummendorf T. H., Balabanov S., Thiede C., Illme T., Schaich M.: Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica, 2005;90:307-316
52. Hayflick L.: The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res., 1965;37:614-636
53. Heaphy C. M., Meeker A. K.: The potential utility of telomere-related markers for cancer diagnosis. J. Cell. Mol. Med., 2011;15:1227-1238
54. Hills M., Lansdorp P. M.: Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. Ann. N. Y. Acad. Sci., 2009;1176:178-190
55. Hirai Y., Masutomi K., Ishikawa F.: Kinetics of DNA replication and telomerase reaction at a single-seeded telomere in human cells. Genes Cells, 2012;17:186-204
56. Hug N., Lingner J.: Telomere length homeostasis. Chromosoma, 2006;115:413-425
57. Jones C. H., Pepper C., Baird D. M.: Telomere dysfunction and its role in haematological cancer. Br. J. Haematol., 2012;156:573-587
58. Joseph I., Tressler R., Bassett E., Harley C., Buseman C. M., Pattamatta P., Wright W. E., Shay J. W., Go N. F.: The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res., 2010;70:9494-9504
59. Kim S., Parks C. G., Xu Z., Carswell G., DeRoo L. A., Sandler D. P., Taylor J. A.: Association between genetic variants in DNA and histone methylation and telomere length. PLoS One, 2012;7:e40504
60. Kirwan M., Vulliamy T., Marrone A., Walne A. J., Beswick R., Hillmen P., Kelly R., Stewart A., Bowen D., Schonland S. O., Whittle A. M., McVerry A., Gilleece M., Dokal I.: Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum. Mutat., 2009;30:1567-1573
61. Lau L. M., Dagg R. A., Henson J. D., Au A. Y., Royds J. A., Reddel R. R.: Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res., 2013;41:e34
62. Letsolo B. T., Rowson J., Baird D. M.: Fusion of short telomeres in human cells is characterized by extensive deletion and microhomology, and can result in complex rearrangements. Nucleic Acids Res., 2010;38:1841-1852
63. Lin J., Epel E., Blackburn E.: Telomeres and lifestyle factors: roles in cellular aging. Mutat. Res., 2012;730:85-89
64. Lundblad V.: Telomere end processing: unexpected complexity at the end game. Genes Dev., 2012;26:1123-1127
65. Maritz M. F., Napier C. E., Wen V. W., MacKenzie K. L.: Targeting telomerase in hematologic malignancy. Future Oncol., 2010;6:769-789
66. Martens U. M., Brass V., Sedlacek L., Pantic M., Exner C., Guo Y., Engelhardt M., Lansdorp P. M., Waller C. F., Lange W.: Telomere maintenance in human B lymphocytes. Br. J. Haematol., 2002;119:810-818
67. Melin B. S., Nordfjäll K., Andersson U., Roos G.: hTERT cancer risk genotypes are associated with telomere length. Genet. Epidemiol., 2012;36:368-372
68. Miller D., Reynolds G. E., Mejia R., Stark J. M., Murnane J. P.: Subtelomeric regions in mammalian cells are deficient in DNA double strand break repair. DNA Repair, 2011;10:536-544
69. Moyzis R. K., Buckingham J. M., Cram L. S., Dani M., Deaven L. L., Jones M. D., Meyne J., Ratliff R. L., Wu J. R.: A highly conserved repetitive DNA sequence, (TTAGGG) n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. USA, 1988;85:6622-6626
70. Mrózek K., Heerema N. A., Bloomfield C. D.: Cytogenetics in acute leukemia. Blood Rev., 2004;18:115-136
71. Muraki K., Nyhan K., Han L., Murnane J. P.: Mechanisms of telomere loss and their consequences for chromosome instability. Front. Oncol., 2012;2:135
72. Murnane J. P.: Telomere dysfunction and chromosome instability. Mutat. Res., 2012;730:28-36
73. Neidle S., Parkinson G. N.: The structure of telomeric DNA. Curr. Opin. Struct. Biol., 2003;13:275-283
74. Nikitina T., Woodcock C. L.: Closed chromatin loops at the ends of chromosomes. J. Cell Biol., 2004;166:161-165
75. Palm W., de Lange T.: How shelterin protects mammalian telomeres. Annu. Rev. Genet., 2008;42:301-334
76. Paul L.: Diet, nutrition and telomere length. J. Nutr. Biochem., 2011;22:895-901
77. Pfeiffer V., Lingner J.: TERRA promotes telomere shortening through exonuclease 1-mediated resection of chromosome ends. PLoS Genet., 2012;8:e1002747
78. Podlevsky J. D., Chen J. J.: It all comes together at the ends: telomerase structure, function, and biogenesis. Mutat. Res., 2012;730:3-11
79. Prescott J., Wentzensen I. M., Savage S. A., De Vivo I.: Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutat. Res., 2012;730:75-84
80. Rudolph K. L., Millard M., Bosenberg M. W., DePinho R. A.: Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet., 2001;28:155-159
81. Rufer N., Brümmendorf T. H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., Schulzer M., Lansdorp P. M.: Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med., 1999;190:157-167
82. Sampathi S., Chai W.: Telomere replication: poised but puzzling. J. Cell. Mol. Med., 2011;15:3-13
83. Savage S. A., Bertuch A. A.: The genetics and clinical manifestations of telomere biology disorders. Genet. Med., 2010;12:753-764
84. Shalev I.: Early life stress and telomere length: investigating the connection and possible mechanisms: a critical survey of the evidence base, research methodology and basic biology. Bioessays, 2012;34:943-952
85. Shammas M. A.: Telomeres, lifestyle, cancer, and aging. Curr. Opin. Clin. Nutr. Metab. Care, 2011;14:28-34
86. Stewart J. A., Chaiken M. F., Wang F., Price C. M.: Maintaining the end: roles of telomere proteins in end-protection, telomere replication and length regulation. Mutat. Res., 2012;730:12-19
87. Verstovsek S., Giles F. J., O'Brien S., Faderl S., Kantarjian H. M., Keating M. J., Albitar M.: Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk. Res., 2004;28:707-711
88. Vousden K. H., Lane D. P.: p53 in health and disease. Nat. Rev. Mol. Cell Biol., 2007;8:275-283
89. Vulliamy T., Beswick R., Kirwan M., Marrone A., Digweed M., Walne A., Dokal I.: Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc. Natl. Acad. Sci. USA, 2008;105:8073-8078
90. Walker J. R., Zhu X. D.: Post-translational modifications of TRF1 and TRF2 and their roles in telomere maintenance. Mech. Ageing Dev., 2012;133:421-434
91. Wang Y., Broderick P., Webb E., Wu X., Vijayakrishnan J., Matakidou A., Qureshi M., Dong Q., Gu X., Chen W. V., Spitz M. R., Eisen T., Amos C. I., Houlston R. S.: Common 5p15. 33 and 6p21.33 variants influence lung cancer risk. Nat. Genet., 2008;40:1407-1409
92. Wang Y., Fang M., Sun X., Sun J.: Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival. Int. J. Lab. Hematol., 2010;32:230-238
93. White L. K., Wright W. E., Shay J. W.: Telomerase inhibitors. Trends Biotechnol., 2001;19:114-120
94. Wolkowitz O. M., Mellon S. H., Epel E. S., Lin J., Dhabhar F. S., Su Y., Reus V. I., Rosser R., Burke H. M., Kupferman E., Compagnone M., Nelson J. C., Blackburn E. H.: Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress - preliminary findings. PLoS One, 2011;6:e17837
95. Wysoczańska B.: Współczesne technologie identyfikacji długo-ści telomerów. W: Badania immunogenetyczne w transplantologii i diagnostyce, red. K. Bogunia-Kubik, I-BIS, Wrocław 2012;160-169
96. Xu L., Li S., Stohr B. A.: The role of telomere biology in cancer. Annu. Rev. Pathol., 2013;8:49-78
97. Xu Y., He K., Goldkorn A.: Telomerase targeted therapy in cancer and cancer stem cells. Clin. Adv. Hematol. Oncol., 2011;9:442-455
98. Young N. S.: Bone marrow failure and the new telomere diseases: practice and research. Hematology, 2012;17(Suppl. 1):S18-S21
99. Zhou X., Xing D.: Assays for human telomerase activity: progress and prospects. Chem. Soc. Rev., 2012;41:4643-4656